US/UK/Canada

Share

Pick a time period -
Tags ( Active)

ColdZyme also blocks omicron variants BA.4 and BA.5

A new study by the Medical University of Innsbruck (MUI) shows that ColdZyme protects airway epithelia from infection with the widespread omicron variants BA.4 and BA.5. This builds upon previous research by the same research group, showing that ColdZyme blocks the original omicron BA.1 variant, which was communicated by Enzymatica in June 2022. The new study is due for publication within the coming months. ColdZyme has now been shown to block 11 respiratory tract viruses and viral sub-variants, including three omicron variants and other coronaviruses. The research group in Innsbruck

Questions and Answers – regarding the ASA decision, for marketing- and web material of ColdZyme in the UK

1.Why has the ASA ruled on the content of your ColdZyme ads and Boots’ website?  ASA is acting on two complaints about claims we have made in a poster and that were made about the product on Boots’ website back in 2014, we have already taken the appropriate corrective action, changing the claims. ASA has the responsibility to see that advertising rules in the CAP code (The UK Code of Non-broadcast Advertising, Sales Promotion and Direct Marketing) in UK are followed and therefore looked into these complaints. 2.What scientific data do you have to support the claims in the ads? We

Launch in Denmark expands ColdZyme® to all of Scandinavia

Enzymatica, which develops and sells medical device products based on an enzyme from deep-sea cod, has signed agreements with the pharmacy chain Pharma+ and the wellness chain Matas in Denmark to sell ColdZyme® against common colds. From November this year, ColdZyme will be available on the Danish market, and thus in all of Scandinavia. "According to plan, we are expanding to our neighboring countries using our own sales organization, building a platform of close relationships with the pharmacy and wellness market throughout Scandinavia. The expanded geographic presence sets the scene

Enzymatica: ColdZyme to be introduced in the UK

Enzymatica, which develops and sells medical products based on enzyme from deep-sea cod, has signed an agreement with AHA Sales and Marketing for the distribution of the company's common cold product ColdZyme® Mouth Spray to pharmacies in the UK. Initially the product will be introduced in the pharmacy-led health and beauty retailer, Boots UK, starting in September 2014. In conjunction with the launch Enzymatica will invest in a media campaign. “We are very pleased to expand into the UK market. We thus meet one of our goals for 2014 - to launch ColdZyme in markets outside Scandinavia.

Enzymatica signs agreement for the sale of ColdZyme® at Swedish airports

The biotechnology company, Enzymatica, has signed an agreement with the pharmaceuticals wholesaler, Pharmaxim, for the distribution of ColdZyme® Mouth Spray at Swedish airports. Pharmaxim supplies all OTC medications to the Nuance Group, which is responsible for all tax-free sales of non-prescription products at Swedish airports. Pharmaxim has placed its initial order, and this has been distributed to the majority of airports in Sweden. Air-passengers are an important target group for Enzymatica’s cold treatment spray. A US study has shown that one in five passengers catch a cold after a

Enzymatica expands its own Scandinavian operation and moves internationally with partners

After the outstanding success of the ColdZyme® Mouth Spray cold treatment in Sweden, Enzymatica has decided to take charge of sales of ColdZyme on the Scandinavian markets itself. For the rest of Europe and other markets, the company will work through licensing and distribution agreements. For these markets, Enzymatica will continue to negotiate with the international pharmaceuticals company, Actavis, but negotiations are also being held with other players. The successful launch of ColdZyme Mouth Spray in Sweden has propelled ColdZyme into the top 10 best-selling cold treatments by value,

Enzymatica: ColdZyme® Mouth Spray on pharmacy chain Medstop’s shelves

The biotechnology company Enzymatica has agreed with the pharmacy chain Medstop that ColdZyme Mouth Spray will be included in the ordinary range of Medstop. The product will be available from next week on Medstop’s 67 pharmacies located in Swedens metropolitan regions Mälardalen, Gothenburg and Skåne. Enzymaticas medical device ColdZyme Mouth Spray against common colds will be on sale in the ordinary range of Medstop´s pharmacy outlets from next week, (week.41). The launch of ColdZyme on Medstop takes place in the middle of the common cold season when demand for products for colds is

Enzymatica conducts a directed issue totalling SEK 19 million

The biotech company, Enzymatica, successfully completed a directed issue yesterday, raising around SEK 19 million before deducting issue expenses, under the authority of a resolution of the annual general meeting held on 6 May. The capital raised will be used primarily in the launch of the new treatment for the common cold, ColdZyme® Mouth Spray, on the Swedish market, and to finance the Company’s on-going research and product development work. At the annual general meeting held on 6 May, the Board was authorised, at its own discretion, to issue a maximum of 2,000,000 new shares with or

Broad launch for ColdZyme® Mouth Spray, soon on Apoteket AB’s shelves

The biotech company Enzymatica has signed an agreement with Apoteket AB, Sweden’s largest pharmacy chain. From early September, Enzymatica’s cold treatment product, ColdZyme® Mouth Spray, will be on sale at Apoteket AB. As of early September, Enzymatica’s registered medical device product against the common cold, ColdZyme® Mouth Spray, will form part of the regular range stocked by Apoteket AB and will be available from outlets throughout Sweden. The launch coincides with the beginning of the usual cold season, i.e. the end of the summer holidays and the start of the school year. - We

Anders Jungbeck proposed as new member of the Board of Enzymatica

Enzymatica strengthens its Board with competency and experience from the pharmaceutical industry. Anders Jungbeck, vice president of the international pharmaceutical company Actavis, has been proposed as new member of the Board of Enzymatica. Anders Jungbeck has the past 29 years been working in both the Swedish and international pharmaceutical industry in companies as Glaxo, Draco, AstraZeneca and Ratiopharm. - We are very pleased to have Anders Jungbeck to candidate for our Board. By having Anders on the Board we get a good gain in terms of experience from the international

Enzymatica to commence clinical market-monitoring study for the prevention and shortening of upper airway infection

Enzymatica’s “COLDPREV” study will commence during the spring. The study – which is placebo controlled – is aimed at investigating the prevention and disease progression in subjects who become inoculated (infected) with the common cold virus. Enzymatica has received approval from the Regional Ethical Review Board in Lund for its ”COLDPREV” clinical study. The study is a randomized, double-blind, and placebo controlled market-monitoring investigation for the CE marked medical device product, ColdZyme® Mouth Spray. The purpose of the study is to deepen knowledge about the prevention and

Enzymatica: ColdZyme® Mouth Spray – for treating the common cold – to be introduced by the Swedish Apotek Hjärtat pharmacy chain

Enzymatica has concluded an agreement with Apotek Hjärtat, Sweden’s second largest pharmacy chain. During February 2013, Enzymatica’s medical device product, ColdZyme® Mouth Spray, will be introduced as part of the product range at Apotek Hjärtat.“The agreement signed with the Apotek Hjärtat pharmacy chain serves as further confirmation of the interest in our products. The Apotek Hjärtat pharmacy chain is Sweden’s second largest pharmacy group, with some 270 pharmacies nationwide,” notes Michael Edelborg Christensen, CEO at Enzymatica. Enzymatica’s registered product, ColdZyme® Mouth

Enzymatica published in the international journal Infectious Diseases & Therapy – promising method for the prevention of colds using ColdZyme Mouth Spray

A recently published systematic review article in Infectious Diseases & Therapy, authored by Enzymatica’s researchers, elucidates the potential of cold-adapted proteases for the treatment of various illnesses. ColdZyme Mouth Spray may offer promising potential as a medical device treatment in reducing the risk of contracting the common cold. Proteases or proteolytic enzymes have been used therapeutically over a protracted period and have displayed major potential in the treatment of a number of illnesses. Cold-adapted proteases offer greater flexibility and catalytic effectiveness than

Enzymatica signs agreement with the Kronans Droghandel pharmacy chain

Enzymatica has concluded its first commercial agreement. This entails that Enzymatica’s medical device product, ColdZyme® Mouth Spray used against the common cold, will be on sale at the Kronans Droghandel pharmacies in early 2013. “The agreement is, of course, commercially important for us, since the pharmacy chains represent a significant factor in our launch strategy. It has been consistently our goal to launch among the pharmacy chains at the beginning of 2013 and thus it is extra gratifying to be able to deliveron schedule,” says Michael Edelborg Christensen, CEO at Enzymatica.

Enzymatica announces Fredrik Håkansson as its new CFO

Enzymatica announces the recruitment of Fredrik Håkansson as its new CFO, Fredrik will assume his position from 1[st] of December. Fredrik has extensive experience in finance and accounting and has held similar positions in several companies, most recently from Systemtext AB where he was CFO.- Fredrik has just the right background and competency. As we establish ourselves in the market, and sales are growing there will also be greater demands on our commercial and financial competency. Here will Fredrik be an asset and strength, said Michael Edelborg Christensen, CEO of Enzymatica AB.

Mats Clarsund new EVP Research & Development at Enzymatica

Enzymatica strengthens research and appoints Mats Clarsund new Executive Vice President for Research and Development. Mats Clarsund has extensive experience in research and business development, the past ten years in senior positions in biotechnology and pharmaceutical industries. Mats Clarsund comes from Alligator Bioscience in Lund, and will assume the position at Enzymatica from November 2012.- Mats have extensive and broad experience from research and development in enzyme technology. Recruitment of Mats represents a strengthening of our research activities and is a clear indication

Enzymatica’s ColdZyme® Mouth Spray against common cold is registered with the Swedish Medical Product Agency

Enzymatica AB (publ) has registered ColdZyme ® Mouth Spray with the Swedish Medical Product Agency as a medical device, Class I. The product is intended for the prevention and treatment of common cold, it may also reduce the duration, if used in the early stages of common cold. The ColdZyme® Mouth Spray is based on an enzyme derived from the deep-sea cod that has been shown to have very good therapeutic characteristics. Negotiations are ongoing with the major pharmacy chains and wholesalers in Sweden for the upcoming large-scale launches in Sweden and the other Nordic countries. · The

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe